Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
about
Gene therapy in Parkinson's disease: rationale and current statusTreatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trialCurrent and future regenerative medicine - principles, concepts, and therapeutic use of stem cell therapy and tissue engineering in equine medicineProgress and prospects: immune responses to viral vectorsEfficient intrathymic gene transfer following in situ administration of a rAAV serotype 8 vector in mice and nonhuman primates.High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectorsInfluence of immune responses in gene/stem cell therapies for muscular dystrophies.Hepatic gene transfer as a means of tolerance induction to transgene productsComparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuriaGene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.Expression of dog microdystrophin in mouse and dog muscles by gene therapyGene therapy with mitochondrial heat shock protein 70 suppresses visual loss and optic atrophy in experimental autoimmune encephalomyelitis.Primate models of schizophrenia: future possibilities.Delivery of human EV71 receptors by adeno-associated virus increases EV71 infection-induced local inflammation in adult mice.Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular diseaseVersatile somatic gene transfer for modeling neurodegenerative diseases.Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.AAV2-mediated in vivo immune gene therapy of solid tumours.Modeling Pulmonary Disease Pathways Using Recombinant Adeno-Associated Virus 6.2.Leber's Hereditary Optic Neuropathy-Gene Therapy: From Benchtop to Bedside.TLR-9 contributes to the antiviral innate immune sensing of rodent parvoviruses MVMp and H-1PV by normal human immune cells.LHON gene therapy vector prevents visual loss and optic neuropathy induced by G11778A mutant mitochondrial DNA: biodistribution and toxicology profile.RETRACTED: Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapySafety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial.Pre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brainCurrent status of pharmaceutical and genetic therapeutic approaches to treat DMD.Acid-degradable cationic dextran particles for the delivery of siRNA therapeutics.Development of viral vectors for use in cardiovascular gene therapy.Intrinsic transgene immunogenicity gears CD8(+) T-cell priming after rAAV-mediated muscle gene transfer.Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer.Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral VectorIntracellular trafficking of polyamidoamine-poly(ethylene glycol) block copolymers in DNA delivery.Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogsExamining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.Effect of nuclear factor κB inhibition on serotype 9 adeno-associated viral (AAV9) minidystrophin gene transfer to the mdx mouse.Novel therapies, high-risk pediatric research, and the prospect of benefit: learning from the ethical disagreements.Control and augmentation of long-term plasmid transgene expression in vivo in murine muscle tissue and ex vivo in patient mesenchymal tissueIntranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaquesThe threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing.Induction of rapid and highly efficient expression of the human ND4 complex I subunit in the mouse visual system by self-complementary adeno-associated virus.
P2860
Q22241423-7DD4E88F-B923-4D62-836F-C5AEFD8EE9D3Q24608049-4B718208-2998-4765-AE78-1DA947859125Q24646497-47B18986-59CA-42EF-B863-5AACF440C4CCQ28264531-B30208C1-8DDD-4893-B451-A7B51CA394BEQ33713355-C74676D4-FC65-4C9F-B8B2-FF7745998890Q33713361-11918629-836A-4316-BC08-047558C35DBCQ33736192-185760E1-1E96-4957-839D-2F2E81EEDDFEQ33775537-E1B36A79-5CA3-4CE7-8AC8-8AA2FC9BF4FEQ33832790-ABF85DC0-C2CD-4F80-ACA1-96FBD61C117FQ33881920-9F79956B-9CC8-4EF4-A160-A4289E5B4F0FQ33931564-165DFFA1-AB81-44EE-B29E-B3DF4D6F4F4FQ34069978-75B40187-2906-49E8-8E8A-7BA803ECD4E0Q34090316-A0ED1EA0-8A98-4195-9E87-D648F5495B87Q34177586-0044099A-44ED-4C88-9FC1-61E2B2FE9668Q34218552-FC9DAF13-EFEE-4B18-85C3-68C81503F173Q34285870-1D5BDECC-B97E-4890-AEA3-1F67316E4FA7Q34370111-F3D47D9E-9ABD-4086-A0AE-59D55B21E3CFQ34468330-1C701C52-5E19-4CE2-A5AB-813E0B52CE63Q34470424-9346AE98-6BE5-4619-93D1-3D8D9BC9B3EFQ34495453-4C626C15-FC6F-4D16-A593-0204295BBC58Q34576048-8FCA7B31-AD46-43AF-B829-19AE74DDA528Q34600009-F43C60D9-7B16-4A3A-90FB-10BB557EE5F8Q34621544-6017F330-D380-42B3-91F2-B43A4E0B93B8Q34700126-FB2F039A-D68F-4067-A100-2653BDC15F12Q34718452-5BB3F9E5-336C-4992-A85C-656A042D0DB1Q34994545-6CB5C95C-530A-4612-B054-B38B5C2B7A2DQ35155064-03458FC7-7B9B-476D-94DC-655E4D0A6750Q35260617-E998F69A-5194-4D14-B15D-D41DC240D346Q35399100-6FCEA990-E0DD-4C62-B83F-76A1981753DDQ35451204-E2B934AA-B0C9-4C39-BCA9-3B8304E402F9Q35513407-1389BDC7-08EE-4AC4-86D9-A59A66D4D804Q35555581-4E77C751-E6B2-4662-85AA-F1FD97B0BFE0Q35823873-29D8DF77-7ED5-41C8-A2E9-BA85298BBD64Q35960506-431BBD8F-A67E-460F-9DDC-DA5A9FF05FF6Q35973260-4B72340E-8AC2-40F0-8E41-7A086A92B5E4Q36014074-AFA1C1C5-7A47-41C3-A751-EAD1E320F73DQ36091207-88728B1D-8679-4575-84A8-AFCD1FB4FB66Q36114234-9AE50941-15E6-4548-8F06-5C26FB6997D4Q36155013-A58FA73F-F635-4DE8-A1FB-819E4E771616Q36202218-0545AA4B-44D4-40B1-8D9F-0C54A16B2E7E
P2860
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
@en
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
@nl
type
label
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
@en
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
@nl
prefLabel
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
@en
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
@nl
P2860
P356
P1433
P1476
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
@en
P2093
P2860
P2888
P304
P356
10.1038/GT.2008.54
P577
2008-04-03T00:00:00Z